Fuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy

Photodiagnosis Photodyn Ther. 2023 Jun:42:103316. doi: 10.1016/j.pdpdt.2023.103316. Epub 2023 Feb 4.

Abstract

Aim: To determine the prevalence of Fuji sign in central serous chorioretinopathy (cCSC) patients and its predictive power of good response to photodynamic therapy (PDT).

Methods: Retrospective study, including 135 eyes of 130 patients diagnosed with cCSC treated with PDT between 2017 and 2021. Optical Coherence Tomography (OCT) images from these patients were compiled and analyzed. The presence of the Fuji sign, an anatomical finding recently described as a predictor of spontaneous resolution of the subretinal fluid (SRF) in cCSC, as assessed in basal images and the maximum height of SRF pre- and post-PDT OCT was measured.

Results: Mean age was 56.6 years, 69.4% were men and the percentage of partial or complete resolution of the SRF after PDT was 75.55%. Only 8.9% of patients (12/135) had positive Fuji sign at baseline OCT. Among them, 50% (6/12) presented a complete response to the PDT (pre-PDT SRF: 109.00 (29.61) µm), 8.3% (1/12) had a partial resolution of the SRF (127 µm to 66 µm) and 41.6% (5/12) did not respond to PDT (pre-PDT SRF: 71.00 (22.82) µm, post-PDT SRF: 83.60 (36.13) µm).

Conclusions: Fuji sign has a low prevalence in cCSC and its presence is not associated with a good response to PDT.

Keywords: Chronic central serous chorioretinopathy; Fuji sign; Photodynamic therapy; Subretinal fluid.

MeSH terms

  • Central Serous Chorioretinopathy* / diagnostic imaging
  • Central Serous Chorioretinopathy* / drug therapy
  • Central Serous Chorioretinopathy* / epidemiology
  • Chronic Disease
  • Female
  • Fluorescein Angiography / methods
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Porphyrins* / therapeutic use
  • Prevalence
  • Retrospective Studies
  • Tomography, Optical Coherence / methods
  • Verteporfin / therapeutic use
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Verteporfin
  • Porphyrins